PulseAugur / Brief
EN
LIVE 12:13:50

Brief

last 24h
[2/2] 222 sources

Multi-source AI news clustered, deduplicated, and scored 0–100 across authority, cluster strength, headline signal, and time decay.

  1. TOOL · 36氪 (36Kr) 中文(ZH) ·

    CStone Pharmaceuticals: Orelabrutinib New Drug Marketing Application for ITP Treatment Accepted

    A new drug, 奥布替尼 (Obutini), developed by Innocare Pharma, has had its new drug application accepted by China's National Medical Products Administration for treating primary immune thrombocytopenia (ITP). This marks the first autoimmune disease indication for 奥布替尼 and addresses a current gap in the market, as no BTK inhibitors are approved for ITP in China. The company anticipates no immediate significant impact on its current financial performance from this development. AI

  2. RESEARCH · 36氪 (36Kr) 中文(ZH) ·

    Li Auto: Delivered 95,142 new vehicles in the first quarter, a year-on-year increase of 2.5%

    Li Auto reported first-quarter deliveries of 95,142 vehicles, a 2.5% increase year-over-year, reclaiming the top sales spot among Chinese brands in the new energy vehicle market above 200,000 yuan. The company's first-quarter revenue reached 23 billion yuan. Additionally, Innocare Pharma announced that its self-developed BTK inhibitor, Obutinib, has received acceptance from China's National Medical Products Administration for its new drug application to treat primary immune thrombocytopenia (ITP). This marks the first time Obutinib's application for an autoimmune disease indication has been accepted, with no other BTK inhibitors currently approved for ITP in China. AI

    IMPACT Minimal direct impact on AI operators; focuses on automotive sales and pharmaceutical regulatory news.